<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01237249</url>
  </required_header>
  <id_info>
    <org_study_id>GEM2010MAS65</org_study_id>
    <nct_id>NCT01237249</nct_id>
  </id_info>
  <brief_title>Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone</brief_title>
  <official_title>A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone (Rd).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a national, multicenter, open-label, randomized, comparative study designed to&#xD;
      compare, first, the TTP of the two treatment schemes proposed (MPV followed by Rd or MPV&#xD;
      alternating with Rd) in newly diagnosed MM patients older than 65 years. This comparison will&#xD;
      be performing in terms of both efficacy and safety. Up to 120 patients will be included in&#xD;
      each treatment arm and evaluated at scheduled visits in up to 3 study periods: Pre-treatment,&#xD;
      Treatment and Follow-up.&#xD;
&#xD;
      Primary outcome measure:&#xD;
&#xD;
        -  To evaluate the efficacy in terms of time to progression (TTP) at 18 months of MPV and&#xD;
           Rd used as either in a sequential or alternating approach in newly diagnosed MM patients&#xD;
           older than 65 years.&#xD;
&#xD;
        -  To evaluate the toxicity (safety and tolerability) of the sequential versus the&#xD;
           alternating use of MPV and Rd.&#xD;
&#xD;
      Secondary outcome measure:&#xD;
&#xD;
        -  To evaluate the response, duration of response, progression free survival (PFS), time to&#xD;
           next therapy (TNT) and overall survival (OS) in the two different groups of patients.&#xD;
&#xD;
        -  To identify, within the group of patients treated with the alternating scheme, the&#xD;
           biological characteristics (including a comprehensive genomic analysis) of those&#xD;
           patients resistant to one or the other, and patients refractory to both treatments&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Pre-treatment period includes Screening visit. After providing written informed consent&#xD;
      form to participate in the study, patients will be evaluated for eligibility during a&#xD;
      screening period of 14 days (Days -14 to -1). If patients meet all inclusion and exclusion&#xD;
      criteria will be randomized at the moment of entry in the trial in a 1:1 allocation to&#xD;
      receive either MPV followed by Rd (Treatment Group A) or MPV alternating with Rd (Treatment&#xD;
      Group B).&#xD;
&#xD;
      Patients in the Treatment Group A will receive nine cycles of MPV consisting on one 6-weeks&#xD;
      cycle of Velcade (Bortezomib) as an intravenous bolus twice weekly (days 1, 4, 8, 11, 22, 25,&#xD;
      29 and 32) followed by a 10 day rest period (day 33 to 42), in combination with oral&#xD;
      Melphalan, once daily on days 1 to 4 and oral Prednisone, once daily on days 1 to 4, followed&#xD;
      by eight 4-weeks cycles of Velcade (Bortezomib) as an intravenous bolus on days 1, 8, 15 and&#xD;
      22 followed by a 6 day rest period (days 23 to 28), in combination with Melphalan and&#xD;
      Prednisone per os once daily on days 1 to 4, followed by a 24-day rest period (days 5 to 28).&#xD;
      After the nine MPV cycles, patients will receive nine cycles of Rd consisting on 4-weeks&#xD;
      cycles, including Revlimid (lenalidomide), once daily on days 1-21 followed by a 7 day rest&#xD;
      period (days 22 to 28) plus oral dexamethasone, once weekly on days 1,8,15 and 22, followed&#xD;
      by a 6 day rest period (days 23 to 28).&#xD;
&#xD;
      Patients in the Treatment Group B will receive the same schedule of therapy, but the MPV&#xD;
      cycles will be alternated with Rd cycles. In this treatment Group B, patients will be again&#xD;
      randomized to start receiving either MPV or Rd as first cycle of therapy. Overall, patients&#xD;
      will receive an identical number of cycles, nine cycles of MPV and nine of Rd. Patients&#xD;
      randomized to Treatment Group A relapsing/progressing or with major toxicities under&#xD;
      treatment with MPV will be crossover to receive Rd, but only after study coordinator&#xD;
      approval.&#xD;
&#xD;
      During the Treatment Period, patients will be evaluated at day 1 of each cycle. After&#xD;
      completion of the Treatment Period, all patients will be evaluated every 2 months thereafter.&#xD;
&#xD;
      Safety will be assessed by the monitoring of adverse events, physical examinations, vital&#xD;
      signs measurements, and haematology and clinical chemistry test. Response to treatment will&#xD;
      be based on EBMT an IMWG criteria. Response to treatment will be evaluated at day 1 of each&#xD;
      induction cycle, and every 2 months during thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy in terms of time to progression (TTP) at 18 months of MPV and Rd used as either in a sequential or alternating approach in newly diagnosed MM patients older than 65 years.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the toxicity (safety and tolerability) of the sequential versus the alternating use of MPV and Rd,in terms of adverse events presented in both groups of patients</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the response in both groups of patients</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify, within the group of patients treated with the alternating scheme, the biological characteristics (including a comprehensive genomic analysis) of those patients resistant to one or the other, and patients refractory to both treatments</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in two groups of patients</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) in two different groups of patients</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next therapy (TNT)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in the two different groups of patients</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>MPV followed by Revlimid/Low Dose Dexamethasone (Rd)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melphalan/Prednisone/Velcade (MPV) followed by Revlimid/Low Dose Dexamethasone (Rd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alternating MPV with Revlimid/Low Dose Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating Velcade/Melphalan/Prednisone (MPV) with Revlimid/Low Dose Dexamethasone (Rd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>MPV followed by Revlimid/Low Dose Dexamethasone (Rd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>MPV followed by Revlimid/Low Dose Dexamethasone (Rd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <arm_group_label>MPV followed by Revlimid/Low Dose Dexamethasone (Rd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revlimid</intervention_name>
    <arm_group_label>Alternating MPV with Revlimid/Low Dose Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Alternating MPV with Revlimid/Low Dose Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained before starting any study-specific procedure.&#xD;
&#xD;
          2. Symptomatic elderly MM newly diagnosed by EBMT criteria older than 65 years.&#xD;
&#xD;
          3. Performance status (ECOG) ≤ 2.&#xD;
&#xD;
          4. Have pre-treatment clinical laboratory values meeting the following criteria within 14&#xD;
             days of randomization:&#xD;
&#xD;
               -  platelet count ≥ 75x109/L&#xD;
&#xD;
               -  haemoglobin ≥ 8g/dL&#xD;
&#xD;
               -  absolute neutrophil count (ANC) ≥ 1.0x109/L&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 mg/dL and alkaline phosphatise ≤ 2.5 x ULN AST, ALT ≤ 2.5 x&#xD;
                  ULN&#xD;
&#xD;
               -  Serum creatinine ≤2,5 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient previously received treatment with Velcade or Revlimid.&#xD;
&#xD;
          2. Patient previously received treatment for Multiple Myeloma.&#xD;
&#xD;
          3. Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrolment.&#xD;
&#xD;
          4. Patient has hypersensitivity to bortezomib, boron, mannitol or lenalidomide.&#xD;
&#xD;
          5. Patient has received other investigational drugs with 28 days before enrolment.&#xD;
&#xD;
          6. Patient had a myocardial infarction within 6 months of enrolment or has New York Heart&#xD;
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe&#xD;
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia or active conduction system abnormalities.&#xD;
&#xD;
          7. Patient currently is enrolled in another clinical research study and/or is receiving&#xD;
             an investigational agent for any reason.&#xD;
&#xD;
          8. Radiation therapy within 30 days before randomization, at least patient has had&#xD;
             antialgic radiation. Radiation therapy will be afterwards permitted during the&#xD;
             treatment period if it is indicated due to the presence of plasmacytomas&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>H. Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Principe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Hospital Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Badalona Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Vall d'Hebron, Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO - Duran i Reynals, Hospitalet de Llobregat</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Castellón</name>
      <address>
        <city>Castellón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General</name>
      <address>
        <city>Ciudad Real</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Luz</name>
      <address>
        <city>Cuenca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Cáceres</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>Donostia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Francesc Borja</name>
      <address>
        <city>Gandía</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO - Josep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. de Jerez</name>
      <address>
        <city>Jerez de la Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario León</name>
      <address>
        <city>Leon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre. Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Fuenlabrada</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Madrid, S.A.- Norte Hospital General</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Tajo</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Sofia</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital la Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Severo Ochoa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Althaia</name>
      <address>
        <city>Manresa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Univeristario Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospital Costa del Sol</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Valme</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Diputación de Navarra</name>
      <address>
        <city>Navarra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Gran Canaria Doctor Negrín</name>
      <address>
        <city>Palma de Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Camino</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoaspital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora del Prado</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia.</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Concha</name>
      <address>
        <city>Zamora</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://aehh.org</url>
    <description>Spanish Association of Hematology</description>
  </link>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>November 4, 2010</study_first_submitted>
  <study_first_submitted_qc>November 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2010</study_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Velcade</keyword>
  <keyword>Revlimid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

